Hematology TimesFDA places full, partial holds on durvalumab trialsSeptember 8, 2017Lymphoma & Plasma Cell DisordersMultiple MyelomaNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesCNS lymphoma responds to CAR T-cell therapyAugust 30, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesDrug receives priority review for FLAugust 29, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesDrug granted breakthrough designation for CTCLAugust 26, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesResearchers estimate risk of death from BIA-ALCLAugust 25, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesHigh healthcare costs follow CCSs into adulthoodAugust 24, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesDrug granted orphan designation for chemo-induced ototoxicityAugust 23, 2017Lymphoma & Plasma Cell DisordersPediatricsPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesAntibody could treat AML, MM, and NHLAugust 22, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAMLNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesDrug granted priority review for CTCLAugust 17, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesNew cancer diagnosis linked to arterial thromboembolismAugust 15, 2017Lymphoma & Plasma Cell DisordersThrombosisNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesAnalysis reveals poor outcomes in refractory DLBCLAugust 12, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFDA grants acalabrutinib breakthrough designationAugust 2, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesDeveloping better mouse modelsJuly 28, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesHigh ORR with sequential regimen in CLLJuly 25, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesCHMP recommends new indication for obinutuzumabJuly 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
